SCHEMBL1689249

SCHEMBL1689249

CC(NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA12 O43570 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CYP2D6 P10635 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 2/20 0.44
EPHX2 P34913 1/20 0.44
CTSK P43235 7/20 0.44
CTSS P25774 3/20 0.44
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23607312 1.00 CA1 (0.52) CA1CA2CA7CA12CA14
SCHEMBL23849248 1.00 CA1 (0.52) CA1CA2CA7CA12CA14
Acetic Acid SCHEMBL3898915 0.94 CA1 (0.47) CA1CA2CA7CA12CA14
SCHEMBL29918031 0.92 KMT2A (0.47) CA1CA2CA7CA12CA14
SCHEMBL29918107 0.92 KMT2A (0.47) CA1CA2CA7CA12CA14
SCHEMBL9744200 0.89 CA1 (0.50) CA1CA2CA7CA12CA14
SCHEMBL2380555 0.89 CA14 (0.59) CA1CA2CA7CA12CA14
SCHEMBL241988 0.89 CA14 (0.59) CA1CA2CA7CA12CA14
SCHEMBL709981 0.89 CA14 (0.59) CA1CA2CA7CA12CA14
Hydrochloric Acid SCHEMBL29367798 0.88 CA14 (0.57) CA1CA2CA7CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220439-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
CN-110475785-A The selection method of peptide compounds and its manufacturing method, screening composition and peptide compounds FUJIFILM CORP 2019-11-19 CN disclosed
WO-2017070518-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed
US-8901353-B2 Polyimide precursor, polyimide, and liquid crystal aligning agent NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2014-12-02 US disclosed
US-20120088888-A1 POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088888-A1 POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT PUF60, F13A1, F12 CA1 247/4885CA2 1637/4885CA7 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.